Medtronic (MDT) stock
NYSE
As of the Nov 5, 2026 close (U.S. Eastern)
- Market cap
- $134.1B
- As of Nov 5, 2026
- P/E
- 25.63x
- Trailing twelve months
- P/B
- 2.67x
- Latest reported equity
- P/S
- 3.57x
- Trailing twelve months
- ROE
- 10.4%
- Trailing twelve months
- Dividend yield
- 2.71%
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
- Market cap
- $134.1B
- As of Nov 5, 2026
- P/E
- 25.63x
- Trailing twelve months
- P/B
- 2.67x
- Latest reported equity
- P/S
- 3.57x
- Trailing twelve months
- ROE
- 10.4%
- Trailing twelve months
- Dividend yield
- 2.71%
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 5, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
25.63x
P/B
2.67x
P/S
3.57x
Earnings and dividend metrics▾
Earnings
EPS
$4.09
Earnings per share
BPS
$39.27
Book value per share
ROE
10.4%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $4.09 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $39.27 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 10.4%.
Dividends
Yield
2.71%
Dividend per share
$2.84
Payout ratio
69.6%
Consecutive years
14+ yrs
Yield uses fiscal 2026 dividends · Dividend per share and payout ratio are for fiscal 2026.
- Dividend yield — dividends divided by the share price (or market cap). It falls when the price rises.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about $284.00 before tax.
- Payout ratio — 69.6% of earnings was paid out as dividends.
- Consecutive years — dividends were paid every year for more than 14 years. That does not mean they will continue.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsMay–Jul 2026(FY2027 Q1)
Revenue increased 13.7% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $8.58B+13.7%
$7.92B
May–Jul '24
$8.58B
May–Jul '25
$9.76B
May–Jul '26
U.S. Eastern date
ⓘ Notes on these figures▾
- Results for May–Jul 2026 are from the 10-Q submitted to SEC EDGAR on Sep 3, 2026.
- Earnings per share increased 40.7% from the same quarter a year earlier.
- Revenue increased 13.7% from the same quarter a year earlier.
- Operating income increased 22.1% from the same quarter a year earlier.
- Net income increased 41.3% from the same quarter a year earlier.
- The next earnings report is scheduled for Nov 17, 2026 (U.S. Eastern).
Filed Sep 3, 2026 · 10-Q · SEC EDGAR · View original
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Marinaro MichaelPresident · Nov 2, 2026Grant or award6,547 shares · $0Avg. price $0113,353 shares held after
- Martha GeoffreyChairman and CEO · Oct 15, 2026Open-market sale50,000 shares · $4.8MAvg. price $95277,866 shares held after
- Marinaro MichaelEVP, Pres MedSurg and Americas · Oct 15, 2026Open-market sale10,420 shares · $1.0MAvg. price $96105,916 shares held after
- Lofton Kevin EDirector · Oct 15, 2026Other182 shares9,977 shares held after
- KIIL HARRY SKIPEVP & President Cardiovascular · Sep 16, 2026Open-market sale1,483 shares · $139KAvg. price $93.6542,186 shares held after
- Blomquist Denise L.Chief Accounting Officer · Sep 15, 2026Gift600 shares · $0Avg. price $016,398 shares held after
- Marinaro MichaelEVP, Pres MedSurg and Americas · Aug 20, 2026Shares withheld for taxes1,084 shares · $100KAvg. price $92.3116,336 shares held after
- Martha GeoffreyChairman and CEO · Aug 3, 2026Grant or award41,533 shares · $0Avg. price $0327,866 shares held after
- Quinn MichelleEVP, GC and Secretary · Aug 3, 2026Grant or award6,346 shares · $0Avg. price $026,721 shares held after
- Marinaro MichaelEVP, Pres MedSurg and Americas · Aug 3, 2026Grant or award57,107 shares · $0Avg. price $0
Show 2 price lots
- 10,960 shares × $0$0
- 46,147 shares × $0$0
- KIIL HARRY SKIPEVP & President Cardiovascular · Aug 3, 2026Grant or award9,230 shares · $0Avg. price $043,669 shares held after
- Thompson KweliEVP & President, Neuroscience · Aug 3, 2026Grant or award6,923 shares · $0Avg. price $035,390 shares held after
- Blomquist Denise L.Chief Accounting Officer · Aug 3, 2026Grant or award2,337 shares · $0Avg. price $016,998 shares held after
- Walter Matthew R.SVP, Chief HR Officer · Aug 3, 2026Grant or award5,769 shares · $0Avg. price $039,928 shares held after
- Pieton ThierryEVP & Chief Financial Officer · Aug 3, 2026Grant or award11,537 shares · $0Avg. price $049,645 shares held after
- Martha GeoffreyChairman and CEO · Jul 31, 2026Shares withheld for taxes15,810 shares · $1.4MAvg. price $85.39286,333 shares held after
- Marinaro MichaelEVP, Pres MedSurg and Americas · Jul 31, 2026Shares withheld for taxes3,356 shares · $287KAvg. price $85.3960,313 shares held after
- KIIL HARRY SKIPEVP & President Cardiovascular · Jul 31, 2026Shares withheld for taxes3,074 shares · $262KAvg. price $85.3934,439 shares held after
- Thompson KweliEVP & President, Neuroscience · Jul 31, 2026Shares withheld for taxes1,739 shares · $148KAvg. price $85.3928,467 shares held after
- Walter Matthew R.SVP, Chief HR Officer · Jul 31, 2026Shares withheld for taxes1,675 shares · $143KAvg. price $85.3934,159 shares held after
- Blomquist Denise L.Chief Accounting Officer · Jul 31, 2026Shares withheld for taxes212 shares · $18KAvg. price $85.3914,661 shares held after
- Quinn MichelleEVP, GC and Secretary · Jul 28, 2026Shares withheld for taxes2,069 shares · $180KAvg. price $86.8820,375 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary8-KThe company said the Board approved on October 15, 2026 the appointment of Michael Marinaro as President, Medtronic, effective October 14, 2026. In this role, he will also oversee the Greater China operations, in addition to his existing responsibilities.Published Oct 19, 2026 · Filed Oct 19, 2026Read the summary →
- AI summary10-QMedtronic said Cardiovascular net sales for the 3 and 6 months ended October 24, 2025 were $3.4 billion and $6.7 billion, respectively, an increase of 11% and 10%, respectively, as compared to the corresponding periods in the prior fiscal year. The company cited growth across most businesses and the impacts of foreign currency fluctuations as drivers of the increase.Published Oct 10, 2026 · Filed Nov 25, 2025Read the summary →
- AI summary8-KThe company reported worldwide revenue of $8.961 billion for fiscal 2026 Q2, which ended October 24, 2025. It said revenue rose 6.6% as reported and 5.5% on an organic basis.Published Oct 9, 2026 · Filed Nov 18, 2025Read the summary →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Medtronic (MDT) stock information
NYSE
Medtronic (MDT) is listed on NYSE. Its market capitalization is about $134.1B. On trailing-twelve-month earnings the P/E ratio is 25.63, and the P/B ratio is 2.67. Return on equity is 10.4%. These figures are computed in-house from official filings and are reference information only.
Medtronic — frequently asked questions
- What is the P/E ratio of Medtronic (MDT)?
- On a trailing-twelve-month basis, MDT trades at a P/E ratio of 25.63. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Medtronic?
- MDT has a market capitalization of about $134.1B. The figure moves with the share price and is refreshed each trading day.
- Does Medtronic pay a dividend?
- MDT has a dividend yield of about 2.71%, based on disclosed payment history. Dividend policy can change; this is reference information only.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.